Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
The DOI matches its Crossref record; 359 of the 359 references it cites were found in a registry or an index.
Abstract
This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It is intended as a guide for the use of antimicrobial agents in managing patients with cancer who experience chemotherapy-induced fever and neutropenia. Recent advances in antimicrobial drug development and technology, clinical trial results, and extensive clinical experience have informed the approaches and recommendations herein. Because the previous iteration of this guideline in 2002, we have a developed a clearer definition of which populations of patients with cancer may benefit most from antibiotic, antifungal, and antiviral prophylaxis. Furthermore, categorizing neutropenic patients as being at high risk or low risk for infection according to presenting signs and symptoms, underlying cancer, type of therapy, and medical comorbidities has become essential to the treatment algorithm. Risk stratification is a recommended starting point for managing patients with fever and neutropenia. In addition, earlier detection of invasive fungal infections has led to debate regarding optimal use of empirical or preemptive antifungal therapy, although algorithms are still evolving. What has not changed is the indication for immediate empirical antibiotic therapy. It remains true that all patients who present with fever and neutropenia should be treated swiftly and broadly with antibiotics to treat both gram-positive and gram-negative pathogens. Finally, we note that all Panel members are from institutions in the United States or Canada; thus, these guidelines were developed in the context of North American practices. Some recommendations may not be as applicable outside of North America, in areas where differences in available antibiotics, in the predominant pathogens, and/or in health care–associated economic conditions exist. Regardless of venue, clinical vigilance and immediate treatment are the universal keys to managing neutropenic patients with fever and/or infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other studies, however, did not observe an association between antimicrobial timing and mortality (112-117).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [113]
In the citing paper
“patients with febrile neutropenia who fail to defervesce after 4–7 days of broad-spectrum antibacterial therapy are at increased risk of having fungal disease (Table 2) [175, 176].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [175]
Citations
Cites
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Self-citationSiegel, J. D., Rhinehart, E., Jackson, M., & Chiarello, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.10.007 · Cited by 3,456
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationBODEY, G. P., BUCKLEY, M., SATHE, Y. S., & FREIREICH, E. J. (1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-2-328 · Cited by 2,469
World Health Organization classification of tumors
Kleihues, P., & Sobin, L. H. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12<2887::aid-cncr32>3.0.co;2-f · Cited by 2,377
Guideline for hand hygiene in health-care settings
Boyce, J. M., & Pittet, D. (2002) · American Journal of Infection Control · doi:10.1067/mic.2002.130391 · Cited by 2,120
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Self-citationPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Self-citation
Research works printed but not linked: 7
- Owens, 2000, Reduction in vancomycin consumption in patients with fever and neutropenia, Clin Infect Dis, 31, 291
- Rotstein, 1997, Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis, Opin Oncol, 4, 2
- Pasqualotto, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613 · DOI
- Ito, 2006, Antibacterial prophylaxis in patients with cancer and neutropenia, N Engl J Med, 354, 90, 10.1056/NEJMc052613 · DOI
- Greene, 2007, Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign, Clin Infect Dis, 44, 373, 10.1086/509917 · DOI · Paper page
- Marks, 2009, Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients [abstract M-1249a]
- National Cancer Center Network (NCCN), 2009, Myeloid growth factors: NCCN practice guidelines
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationStevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu296 · Cited by 2,780
The negative impact of antibiotic resistance
Friedman, N. D., Temkin, E., & Carmeli, Y. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.12.002 · Cited by 870
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Evaluation and Management of Penicillin Allergy: A Review
Shenoy, E. S., Macy, E., Rowe, T., & Blumenthal, K. G. (2019) · JAMA · doi:10.1001/jama.2018.19283 · Cited by 830
Carbapenem Resistance: A Review
Codjoe, F., & Donkor, E. (2017) · Medical Sciences · doi:10.3390/medsci6010001 · Cited by 746
The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens
Kim, S., Covington, A., & Pamer, E. G. (2017) · Immunological Reviews · doi:10.1111/imr.12563 · Cited by 741
Nicolle, L. E., Gupta, K., Bradley, S. F., Colgan, R., DeMuri, G. P., Drekonja, D., Eckert, L. O., Geerlings, S. E., Köves, B., Hooton, T. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz021 · Cited by 737
Azoulay, E., Mokart, D., Pène, F., Lambert, J., Kouatchet, A., Mayaux, J., Vincent, F., Nyunga, M., Bruneel, F., Laisne, L.-M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2365 · Cited by 638
Averbuch, D., Orasch, C., Cordonnier, C., Livermore, D. M., Mikulska, M., Viscoli, C., Gyssens, I. C., Kern, W. V., Klyasova, G., Marchetti, O., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.091025 · Cited by 632
Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K. V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00374 · Cited by 601
Self-citationShono, Y., Docampo, M. D., Peled, J. U., Perobelli, S. M., Velardi, E., Tsai, J. J., Slingerland, A. E., Smith, O. M., Young, L. F., Gupta, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2311 · Cited by 592
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Hill, J. A., Li, D., Hay, K. A., Green, M. L., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., Boeckh, M., & Turtle, C. J. (2018) · Blood · doi:10.1182/blood-2017-07-793760 · Cited by 576
Self-citationNicolle, L. E., Gupta, K., Bradley, S. F., Colgan, R., DeMuri, G. P., Drekonja, D., Eckert, L. O., Geerlings, S. E., Köves, B., Hooton, T. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1121 · Cited by 559
Flowers, C. R., Seidenfeld, J., Bow, E. J., Karten, C., Gleason, C., Hawley, D. K., Kuderer, N. M., Langston, A. A., Marr, K. A., Rolston, K. V. I., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8661 · Cited by 448
Self-citationTaplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6211 · Cited by 426
Self-citationMotsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 422
Groll, A. H., Castagnola, E., Cesaro, S., Dalle, J.-H., Engelhard, D., Hope, W., Roilides, E., Styczynski, J., Warris, A., & Lehrnbecher, T. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70017-8 · Cited by 407
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Gafter-Gvili, A., Fraser, A., Paul, M., Vidal, L., Lawrie, T. A., van de Wetering, M. D., Kremer, L. C., & Leibovici, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004386.pub3 · Cited by 383
Schiffer, C. A., Mangu, P. B., Wade, J. C., Camp-Sorrell, D., Cope, D. G., El-Rayes, B. F., Gorman, M., Ligibel, J., Mansfield, P., & Levine, M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5733 · Cited by 368
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Self-citationLehrnbecher, T., Phillips, R., Alexander, S., Alvaro, F., Carlesse, F., Fisher, B., Hakim, H., Santolaya, M., Castagnola, E., Davis, B. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7161 · Cited by 353
Infections in Cancer Patients with Solid Tumors: A Review
Rolston, K. V. I. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0146-1 · Cited by 334
Self-citationBlot, S., Ruppé, E., Harbarth, S., Asehnoune, K., Poulakou, G., Luyt, C.-E., Rello, J., Klompas, M., Depuydt, P., Eckmann, C., et al. (2022) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2022.103227 · Cited by 333
Gut microbiota injury in allogeneic haematopoietic stem cell transplantation
Shono, Y., & van den Brink, M. R. M. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.10 · Cited by 309
Hill, J. A., & Seo, S. K. (2020) · Blood · doi:10.1182/blood.2019004000 · Cited by 305
Montassier, E., Batard, E., Gastinne, T., Potel, G., & Cochetière, M. F. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-1819-7 · Cited by 304
Adegoke, A. A., Stenström, T. A., & Okoh, A. I. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02276 · Cited by 301
Survival in neutropenic patients with severe sepsis or septic shock*
Legrand, M., Max, A., Peigne, V., Mariotte, E., Canet, E., Debrumetz, A., Lemiale, V., Seguin, A., Darmon, M., Schlemmer, B., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31822b50c2 · Cited by 281
Park, J. H., Romero, F. A., Taur, Y., Sadelain, M., Brentjens, R. J., Hohl, T. M., & Seo, S. K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy152 · Cited by 276
Averbuch, D., Tridello, G., Hoek, J., Mikulska, M., Akan, H., Yaňez San Segundo, L., Pabst, T., Özçelik, T., Klyasova, G., Donnini, I., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix646 · Cited by 271
Satlin, M. J., Jenkins, S. G., & Walsh, T. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu052 · Cited by 255
Weber, D., Jenq, R. R., Peled, J. U., Taur, Y., Hiergeist, A., Koestler, J., Dettmer, K., Weber, M., Wolff, D., Hahn, J., et al. (2017) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.02.006 · Cited by 245
Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
(2021) · doi:10.3322/caac.21697 · Cited by 201
Castanheira, M., Messer, S. A., Rhomberg, P. R., & Pfaller, M. A. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.02.009 · Cited by 159
Stoma, I., Littmann, E. R., Peled, J. U., Giralt, S., van den Brink, M. R. M., Pamer, E. G., & Taur, Y. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa068 · Cited by 142
Galloway-Peña, J. R., Shi, Y., Peterson, C. B., Sahasrabhojane, P., Gopalakrishnan, V., Brumlow, C. E., Daver, N. G., Alfayez, M., Boddu, P. C., Khan, M. A. W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz777 · Cited by 140
ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo
Rolle, A.-M., Hasenberg, M., Thornton, C. R., Solouk-Saran, D., Männ, L., Weski, J., Maurer, A., Fischer, E., Spycher, P. R., Schibli, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518836113 · Cited by 134
Vallabhaneni, S., Benedict, K., Derado, G., & Mody, R. K. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw268 · Cited by 98
Koehler, P., Hamprecht, A., Bader, O., Bekeredjian-Ding, I., Buchheidt, D., Doelken, G., Elias, J., Haase, G., Hahn-Ast, C., Karthaus, M., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.10.019 · Cited by 91
Micafungin breakthrough fungemia in patients with hematological disorders
Kimura, M., Araoka, H., Yamamoto, H., Nakamura, S., Nagi, M., Yamagoe, S., Miyazaki, Y., Ogura, S., Mitsuki, T., Yuasa, M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02183-17 · Cited by 37
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
Vazquez, L. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.040 · Cited by 34
Biofilms and beyond: Expanding echinocandin utility
Larkin, E. L., Dharmaiah, S., & Ghannoum, M. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx451 · Cited by 31
The Microbiota: A New Variable Impacting Cancer Treatment Outcomes
Fessler, J. L., & Gajewski, T. F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0864 · Cited by 24
The role of microbiota in allogeneic hematopoietic stem cell transplantation
Chang, C.-C., Hayase, E., & Jenq, R. R. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1872541 · Cited by 20
Suzuki, H., Perencevich, E. N., Diekema, D. J., Livorsi, D. J., Nair, R., Kralovic, S. M., Roselle, G. A., & Goto, M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab105 · Cited by 20
Invasive Aspergillosis in Hematological Patients
Kimura, S.-I. (2016) · Medical Mycology Journal · doi:10.3314/mmj.57.j77 · Cited by 14
Raouf, M. M. E., Ouf, N. M., Elsorady, M. A. S., & Ghoneim, F. M. (2023) · Virology Journal · doi:10.1186/s12985-023-01980-w · Cited by 9
Trends of antifungal use based on sales data in Japan from 2006 to 2015
Kawabe, A., Muraki, Y., Inose, R., Kusama, Y., Goto, R., Ebisui, A., Ishii, S., Ishikane, M., Ohge, H., & Ohmagari, N. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00302 · Cited by 9
Metadata
- Authors
- Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R.
- Affiliations
- University of Nebraska Medical Center (US)
- CancerCare Manitoba (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Fred Hutch Cancer Center (US)
- City Of Hope National Medical Center (US)
- University of Rochester Medicine (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Minnesota (US)
- University of Florida (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02-15
- Volume
- 52
- Issue
- 4
- Pages
- e56-e93
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2123859227
- Semantic Scholar
- 61f444a63e765b8981339be50b8136ae0b15cb08
- Cited by
- 3,463
- References
- 359
- Citations by year
- 2026: 176 · 2025: 180 · 2024: 163 · 2023: 211 · 2022: 233 · 2021: 245 · 2020: 260 · 2019: 277 · 2018: 254 · 2017: 267 · 2016: 218 · 2015: 247 · 2014: 248 · 2013: 221 · 2012: 174
- FWCI
- 112.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- febrile neutropenia, cancer, chemotherapy-induced neutropenia, antibiotic prophylaxis, antifungal prophylaxis, antiviral prophylaxis, risk stratification, invasive fungal infections, preemptive antifungal therapy, empirical antibiotic therapy, infection management
- MeSH terms
- Anti-Infective Agents, Antineoplastic Agents, Canada, Communicable Diseases, Fever of Unknown Origin, Humans, Neoplasms, Neutropenia, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.